The Centers for Medicare & Medicaid Services (CMS) regulate all clinical laboratory testing performed on humans in the United States with certification through the Clinical Laboratory Improvement Amendments (CLIA) and accreditation by the College of American Pathologists (CAP).
To support clinical applications, GENEWIZ has established next generation sequencing and Sanger-based CLIA-compliant workflows ensuring high-quality laboratory testing for accurate and consistent sequencing results.
CLIA Next Generation Sequencing
Probe protein-coding regions of the genome at high depth with uniform coverage.
Uncover mutations in coding and non-coding regions, including structural and copy number variants.
CLIA Sanger-Based Services
CLIA Sanger sequencing is best utilized to elucidate complex regions or to confirm variants uncovered by genome-wide techniques.
Variant Confirmation (PCR + Sanger)
Reliable method for initial analysis or orthogonal confirmation of next generation sequencing, microarrays, or qPCR results.